🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Leeds
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Leeds

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2846 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 20 Sep 2026, 03:15 UTC
2846
Studies in scope
industry-sponsored, all four open statuses
1377
Recruiting now
open to new participants
539
Lead sponsors
across recruiting studies
Top sites
London 73 Manchester 28 Sutton 25 Birmingham 17 Cambridge 15
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca27 Janssen Research & Development, LLC14 BeOne Medicines9 AbbVie9 Bristol-Myers Squibb9 Clear sponsor filter
Site city
London73 Manchester28 Sutton25 Birmingham17 Cambridge15
All 92 cities
Target enrolment
to
14 of 2846 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094Colorectal Neoplasms
Janssen Research & Development, LLC
Phase 3
700
Birmingham, Hull, Leeds, London, Northwood
2024-12-12
Active, closed
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969Sjogrens Syndrome
Janssen Research & Development, LLC
Phase 3
655
Cambridge, Doncaster, Greater London, Leeds, Liverpool, London, Peterborough, Swindon
2024-12-04
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786Colorectal Neoplasms
Janssen Research & Development, LLC
Phase 3
1,000
Birmingham, Cambridge, Edinburgh, Hull, Leeds, London, Northwood, Sutton
2024-10-18
Active, closed
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
838
Blackpool, Cardiff, Dundee, Leeds, London, Nottingham, Plymouth, Portsmouth
2024-01-22
Recruiting
A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
NCT05912517Hemolytic Disease of the Fetus and Newborn
Janssen Research & Development, LLC
Phase 3
120
Birmingham, Leeds, London, Manchester, Oxford
2023-12-20
Active, closed
A Study of Daratumumab
NCT05438043Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
213
Leeds, Leicester, Surrey, Wolverhampton
2022-12-15
Active, closed
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
NCT04929210Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 4
411
Barnet, Bradford, Coventry, Leeds, Manchester, Newcastle, Stoke-on-Trent
2021-08-30
Active, closed
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
NCT04923893Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
743
Birmingham, Bristol, Leeds, London, Manchester, Surrey
2021-08-19
Recruiting
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
NCT04811560Acute Leukemia
Janssen Research & Development, LLC
Phase 1/2
420
Cardiff, Leeds, Liverpool, London, Manchester, Oxfordshire, Plymouth
2021-05-19
Active, closed
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
NCT04640623Urinary Bladder Neoplasms
Janssen Research & Development, LLC
Phase 2
220
Glasgow, Leeds
2020-12-18
Active, closed
Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
NCT04794101X-Linked Retinitis Pigmentosa
Janssen Research & Development, LLC
Phase 3
97
Edinburgh, Glasgow, Leeds, London
2020-12-04
Active, closed
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia
NCT04119050Warm Autoimmune Hemolytic Anemia
Janssen Research & Development, LLC
Phase 2/3
118
Leeds, Liverpool, London, Oxford, Plymouth, Southampton
2019-08-15
Active, closed
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT03462719Leukemia, Lymphocytic, Chronic, B-Cell
Janssen Research & Development, LLC
Phase 3
211
Birmingham, Cambridge, Charterhouse Square, Glasgow, Leeds, Plymouth, Romford, Sheffield
2018-04-17
Recruiting
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Janssen Research & Development, LLC
Phase 3
700
Birmingham, Bournemouth, Colchester, Glasgow, Leeds, Leicester, London, Manchester
2013-09-09
Rows per page Showing 1–14 of 14
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-uk/city/leeds

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.